Epicrispr Biotechnologies (Series B)

Funding Details
Awarder
Inbox
Date Award
March 26, 2025
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount:
$68,000,000

Company Info
Founders
Amber Salzman
Company Description
Epicrispr Biotechnologies is a biotechnology company pioneering gene-modulating therapies, leading with treatments for neuromuscular diseases. The company's proprietary Gene Expression Modulation System (GEMS) enables precise, durable control of gene expression, unlocking first-in-class treatments for previously untreatable conditions.
Market
Gene-modulating therapies for neuromuscular diseases
Location
South San Francisco, California, USA
Coinvestors
Ally Bridge Group

Links